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Abstract Electrochemical reduction behavior of Adefovir was studied using Hanging Mercury
Drop Electrode (HMDE) in Britton–Robinson (BR) buffer solution. Voltammetric study showed
one well-deﬁned reduction peak in the potential range 1.2 to 1.4 V (vs. Ag/AgCl) due to
reduction of C¼N bond of the imidazole ring. Solid-phase extraction and protein-precipitation
techniques were employed for extraction of Adefovir from human plasma. The proposed method
allows quantiﬁcation of Adefovir in human plasma over the concentration range 0.50–5.00 mg/mL
with the detection limit 0.17 mg/mL, whereas in pharmaceutical formulation 0.25–2.25 mg/mL with
the detection limit 0.08 mg/mL.
& 2011 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.
1. Introduction
Hepatitis B Virus (HBV) infection is a major global health
problem. An estimated 2 billion people worldwide are infected
with the HBV and about 350 million are chronically infected,
which results in 0.6 million deaths every year [1]. Adefovir is
an anti-hepatitis drug, which is found to be very effective
against HBV. Adefovir dipivoxil (9-[2-[[Bis[(pivaloyloxy)-
methoxy]phosphinyl]methoxy]ethyl]adenine) is a nucleotide
analog, an oral prodrug of Adefovir (9-(2-phosphonomethoxy-
ethyl)adenine) (Fig. 1), which rapidly converts into the parent
drug in the body and suppresses the replication of HBV that is
even resistant to other anti-HBV drugs such as lamivudine,
emtricitabine and famciclovir [2–4].
The widespread use of this compound and the need for
clinical and pharmacological studies warrant fast and sensitive
analytical techniques for the assay of drug in pharmaceutical
formulations, biological matrixes and also for toxicological
and pharmacokinetic studies.
Several techniques have been explored for detection and
quantiﬁcation of Adefovir in pharmaceutical formulation and
biological ﬂuids such as spectrophotometry [5], high performance
liquid chromatography [6,7], ion-pair liquid chromatography
[8,9], hydrophilic interaction liquid chromatography–tandem
mass spectrometry [10] and liquid chromatography–tandem mass
spectrometry [11,12]. Although spectrophotometry and chroma-
tography are the most commonly employed techniques, but these
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Figure 1 Chemical structure of Adefovir dipivoxil.
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approaches prior to ﬁnal analysis. These techniques are very time
consuming and the demand of expensive, sophisticated instru-
mentation and highly skilled personnel restrict their use in
routine analysis. Since the last decade, electroanalytical techni-
ques have been widely used in the ﬁeld of pharmaceuticals
analysis [13–18], as these techniques are inexpensive, rapid and
do not require derivatization or the time consuming puriﬁcation
steps after extraction, when compared with other analytical
techniques [8–12]. However, no electro-analytical methods have
yet been reported for the quantiﬁcation of Adefovir in pharma-
ceutical formulations and human plasma.
The purpose of the present study is to develop fast and
sensitive voltammetric method for the detection and quantiﬁ-
cation of Adefovir in pharmaceutical formulations and human
plasma using square-wave adsorptive stripping voltammetry
and cyclic voltammetry due to higher sensitivity, simplicity
and lower limit of detection.2. Experimental
2.1. Instrumentation
Electrochemical measurements were performed using m Auto-
lab Type III potentiostat–galvanostat (Eco-Chemie B.V.,
Utrecht, Netherlands) with 757VA computrace software.
The electrodes utilized in the study were hanging mercury
drop electrode as working electrode, platinum wire as aux-
iliary electrode and Ag/AgCl (3 M KCl) as reference electrode.
All pH measurements were obtained from digital pH meter
(Decible DB-1011) ﬁtted with a glass electrode and saturated
calomel electrode as reference, which was previously standar-
dized with standard buffer solutions of known pH.
2.2. Reagents and chemicals
Adefovir standard (99.43%) was obtained from Veeda Clinical
Research Pvt. Ltd., India. Adefovir-containing tablets from
different companies (labeled 10 mg Adefovir/Tablet) were
obtained from commercial sources. Ultra pure water (Milli-
Q puriﬁcation system, Millipore Corp., Milford, MA, USA),
was used throughout the studies. All chemicals employed in
this work were of analytical reagent grade (Merck and Sigma
Aldrich) and used without further puriﬁcation.
2.3. Analytical procedure
Standard stock solution of Adefovir (1.0 mg/mL) was prepared
by dissolving pure compound in methanol. Working solutions
were prepared from stock solution using a mixture of methanol
and water (50:50, v/v) as diluents. Drug free human blood plasma
lots were procured from Radha Swami blood bank, Gwalior,
India and sodium heparin was used as anticoagulant. These
plasma lots were preserved at 20 1C in freezer and used aftergentle thawing at room temperature. Plasma calibration and
quality control samples were prepared by 5% spiking of
respective working solutions in blank plasma. Analyte was
extracted from spiked human plasma samples using solid-phase
extraction (SPE) and protein precipitation (PP) techniques. For
electrochemical measurements, a known volume of working
solution was pipetted into a voltammetric cell and the total
volume of 10 mL was obtained with BR buffer. Square wave and
cyclic voltammogram were recorded after optimization of opera-
tional parameters.
2.4. Extraction procedure
SPE technique was used to extract Adefovir from human
plasma samples. 500 mL of each calibrator and quality control
samples were transferred to 1.5 mL eppendorf tubes. 250 mL BR
buffer (pH 7.9) was then added to each sample and vortexed for
30 s. After vortexing, samples were centrifuged at 3500 rpm for
5 min. SPE was performed using Oasis HLB cartridges (30 mg/
cc), a vacuum manifold device and a vacuum source. SPE
cartridges were conditioned and equilibrated with 1.0 mL of
methanol followed by 1.0 mL of water. Each sample solution
was individually transferred to a solid-phase extraction cartridge
and passed through the beds at a constant ﬂow rate of 1.0 mL/
min. The cartridges were washed with 1.0 mL of BR buffer (pH
7.9) and allowed to dry. The analytes were eluted with 1.0 mL of
methanol and analysis was performed by aforementioned
method.3. Results and discussion
Reduction behavior of Adefovir was investigated on HMDE
using Square-Wave Voltammetry (SWV), Square-Wave Cathodic
Adsorptive Stripping Voltammetry (SWCAdSV) and Cyclic
Voltammetry (CV). In all the electro-analytical techniques
well-deﬁned reduction peaks were obtained in the potential range
of 1.2 to 1.4 V (vs. Ag/AgCl) due to reduction of the C¼N
bond of the imidazole ring, which was used for analytical
measurements.
3.1. Effect of pH
The pH of supporting electrolyte is an important factor that
affects the redox reaction of analyte. Hence, it is usually important
to investigate the effect of pH in electro-analytical system. In order
to optimize pH, the effect of pH on the reduction of Adefovir was
studied in the range of 2.5–12. Fig. 2 shows the effect of pH on
potential shift and current response. It revealed that the reduction
peak current was the highest at pH 3.8 along with sharpest peak
(Fig. 2, curve c). The peak potential was shifted towards more
negative potential with increasing pH in the range 2.5–4.5 (Fig. 2,
curves a–d), but after pH 4.5 no response was obtained. Therefore,
BR buffer pH 3.8 was selected for the study purpose.
3.2. Selection of extraction technique
Two extraction techniques, PP and SPE were used for
extraction of Adefovir from spiked human plasma. Both
methanol and acetonitrile were used for protein precipitation.
Better results were obtained from acetonitrile (Fig. 3A, curve
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Figure 2 Effect of pH on the cathodic peak current (ip/A) and
potential shift of Adefovir (1.5 mg/mL) at hanging mercury drop
electrode in BR buffer: a¼2.5 pH, b¼3.0 pH, c¼3.8 pH,
d¼4.5 pH.
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R. Jain, R. Sharma100b) as against methanol (Fig. 3A, curve a). However, SPE
technique gave a higher current response, lower background
noise and sharper peak than PP technique (Fig. 3B). Thus,
SPE technique was selected for extraction of Adefovir from
spiked human plasma. Square wave voltammograms obtained
through both extraction techniques are depicted in Fig. 3.-0.60
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Figure 3 Square-wave voltammogram of Adefovir (1.5 mg/mL)
extracted from human plasma, protein precipitation by methanol
(A, curve a), protein precipitation by acetonitrile (A, curve b) and
solid phase extraction (B).3.3. Optimization of voltammetric conditions
Reduction behavior of Adefovir was investigated at HMDE in
BR buffer solution using square-wave and cyclic voltammetry.
For best results both techniques require optimization of
several instrumental and operational parameters. Instrumental
variables such as frequency (f), accumulation time (tacc),
accumulation potential (Eacc), scan rate (Ds) pulse amplitude
(DEsw), etc. were examined.
Frequency was varied from 10–90 Hz. A linear relationship
was obtained between the peak current and frequency of the
signal. In order to improve the sensitivity without any distortion
of the peak or the baseline, frequency 50 Hz was chosen.
Fig. 4 shows the overloaded cyclic voltammograms (Fig. 4A)
and square-wave voltammograms (Fig. 4B) of Adefovir (1.50 mg/
mL) at different accumulation time (tacc). The peak height
depends on the accumulation time, suggesting an effective
adsorption of Adefovir on the HMDE. Peak current increased
with increasing deposition time till 80 s but after 80 s it started
decreasing. It was expected that this phenomenon may be related
to the saturated adsorption of Adefovir on the HMDE surface.
Accumulation time of 30 s was selected for the study purpose.
The effect of accumulation potential (Eacc) on the peak
current (ip/A) of Adefovir was examined over the potential
range 0.1 to 0.9 V (vs. Ag/AgCl). At an accumulation
potential of 0.1 V there was a slightly steep line, which
increased gradually after 0.2 to 0.9 V. Thus, the accumula-
tion potential was ﬁxed at 0.9 V (vs. Ag/AgCl) and used
throughout the study. Effect of scan increment (Ds) on the
square-wave peak current of the drug was also studied. It
revealed that the peak current increased linearly up to scanincrement of 2–10 mV/s. Thus, scan increment 10 mV/s was
used for the study purpose. Pulse amplitude (Esw) was
examined at f 50 Hz and Ds 10 mV/s. The current increased
linearly up to Esw 10–50 mV/s after that peak distortion
resulted in a poorer resolution. Thus, Esw 50 mV/s was
selected for the study purpose. Several operational parameters,
which directly affect the voltammetric response, were also
optimized such as purge time 25 s, stirring rate 2000 rpm,
mercury drop size 4 cm2, cleaning potential 0.2 V, cleaning
time 10 s and equilibration time 10 s.3.4. Cyclic voltammetric behavior
Cyclic voltammetric investigation of Adefovir was performed
on surface of the HMDE in BR buffer solution (pH 3.8) at
different potential sweep rates. Adefovir exhibited one well-
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Figure 4 Cyclic voltammograms of Adefovir (1.50 mg/mL) at tacc
0.0 s (A, curve b), at tacc 30 s (A, curve c) and blank solution (A,
curve a) and square-wave voltammograms at tacc 0.0 s (B, curve a)
and at tacc 30 s (B, curve b).
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(vs. Ag/AgCl), at all concentration levels. No peak could be
observed in the anodic side of the reverse scan, indicating
irreversible nature of the electrode process. The relation
between the cathodic peak current (ip/mA), the diffusion
coefﬁcient of the electroactive species, D0 (cm
2 s1) and the
sweep rate, n (mV/s) is given by the following expression [19]:
ip=mA¼ ð2:99 105Þna1=2ACn0D1=20 n1=2 ð1Þ
where n is the number of electrons exchange in the reduction
process, a is the electron-transfer coefﬁcient for an irreversible
process, A is the surface area of the working electrode (cm2),
and C0
n is the concentration of the electro active species.
Cathodic peak current showed linear variation on varying
sweep rate 50–175 mV/s at a ﬁxed concentration. The relation-
ship between the reduction peak potential and sweep rate
showed that the peak potential shifted negatively and peak
current increased steadily with increasing sweep rate. This
showed the irreversibility of electrode process at HMDE. The
linear regression equation obtained for the cathodic peakcurrent is ip/mA¼0.0388 n (mV/s)þ0.0452 with a correlation
coefﬁcient (r2) of 0.9972. This result indicated that the
electrochemical response of Adefovir at the hanging mercury
drop electrode is an adsorption-controlled process.
3.5. Validation of proposed method
Validation was conducted as per ICH and USFDA guidelines
for assay of Adefovir in pharmaceutical formulation and
human plasma [20,21]. The proposed method was validated
using the following criteria: system suitability, speciﬁcity,
selectivity, linearity, recovery and robustness.
3.5.1. System suitability
The signiﬁcance of system suitability experiment is to ensure that
analytical system (including reagents, electrodes, instrument and
analysts) is adequate for the intended analysis. Six replicate
voltammetric readings of extracted plasma sample of Adefovir
and Adefovir standard solution (1.50 mg/mL) were recorded and
the relative standard deviation (% RSD) was calculated, 1.481%
for extracted plasma sample and 1.582% for standard solution.
3.5.2. Speciﬁcity
Speciﬁcity is the ability of the analytical method to measure the
analyte with acceptable accuracy and precision in the presence of
other interferences. The speciﬁcity of the method for estimation of
Adefovir dipivoxil was evaluated in presence of different concen-
trations of various excipients like pregelatinized starch, croscar-
mellose sodium, lactose monohydrate, talc and magnesium
stearate. No interferences could be observed at reduction of
Adefovir dipivoxil. The response of the analyte in the presence
of excipients was compared with that of the pure Adefovir. It was
found that assay result did not change.
3.5.3. Selectivity
In order to evaluate levels of endogenous compounds and to
develop more sensitive and discriminating methods for quantiﬁca-
tion of analyte with less interference from other components, six
different blank plasma lots were analyzed and these lots were also
used to generate calibration curves. Six lower limit of quantiﬁca-
tion (LLOQ) level samples (0.50 mg/mL) and six blank samples
one from each plasma lots were prepared. These plasma samples
were extracted by SPE method and analyzed. In all plasma blanks,
the response at the potential of Adefovir was less than 20%
(acceptance criteria: r20%) of LLOQ response and no other
endogenous peak was observed in voltammogram.
3.5.4. Linearity
Linearity for assay of Adefovir was performed by standard
addition method. An excellent linearity was observed over a wide
concentration range of 0.25–2.25 mg/mL (nine concentration
levels) with a correlation coefﬁcient (r2) of 0.9977. The calibration
plot resulted in a straight line, ip/mA¼0.4109C0n(mg/mL)0.0041.
Limit of detection was found to be 0.08 mg/mL, lower than this,
peak could not be resolved from background noise. The reduction
peak current of the calibration standard was proportional to
the concentrations of Adefovir over the testing range. In aqueous
solution, accuracy of all calibration standards was within
85–115%, except LLOQ, where it was 80–120%.
Various statistical parameters for linear regression equation like
slope, standard deviation, intercept, standard deviation,
Table 1 Square-wave voltammetric method validation
parameters for standard and extracted plasma linearity.
Linearity parameters Standard Plasma
Slope 0.4109 0.2350
Standard deviation 0.0075 0.0039
Intercept 0.0041 0.0395
Standard deviation 0.0105 0.0120
Correlation coefﬁcient 0.9977 0.9984
Standard error of estimation 0.0145 0.0168
Sum of squares of regression 0.6332 1.0547
Sum of squares of residuals 0.0015 0.0017
Limit of detection (mg/mL) 0.08 0.17
Limit of quantiﬁcation (mg/mL) 0.26 0.51
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Figure 5 Square-wave voltammograms of Adefovir at different
concentration levels, 0.25–2.25 mg/mL (A, curves b–j) and blank
solution (A, curve a) and plot of concentration vs. current (B).
Table 2 Recovery of the Adefovir in human matrix and
in pharmaceutical formulation.
Recovery level Human
matrix
Pharmaceutical
formulation
Recovery level-1 [LQC]a (%) 51.02 99.10
Recovery level-2 [MQC]a (%) 50.51 99.00
Recovery level-3 [HQC]a (%) 50.75 99.50
Mean recovery (%) 50.76 99.20
% CV of mean recovery 0.50 0.27
aRecovery at each level represents the average of six
observations (n¼6).
R. Jain, R. Sharma102correlation coefﬁcient, standard error of estimation, sum of square
of regression and sum of square of residual were calculated and
are listed in Table 1. Representative square-wave cathodic
adsorptive voltammograms and plot of Adefovir concentration
(mg/mL) vs. peak current (ip/mA) are shown in Fig. 5.3.5.5. Recovery
The recovery of an analyte is the detector response, which
is obtained from a known amount of the analyte added
to and extracted from the biological matrix by speciﬁc
extraction method. Absolute recovery experiment was per-
formed by comparing extracted quality control (QC)samples of three different concentration levels (LQC, MQC
and HQC) in six replicates with un-extracted samples of the
same levels. The results indicated that the recovery of Adefovir
from human plasma was greater than 50% at all levels
(Table 2).
Formulation product recovery experiment was carried out
by standard addition method. For this, known concentration
sample of pure Adefovir was mixed with deﬁnite amount of
pre-analyzed formulations of the drug and the mixtures were
analyzed as before at three different concentration levels in six
replicates. The total amount of the drug was then determined
and the amount of the added drug was calculated by the
difference. The results of recovery studies were found to be
quantitative, which are listed in Table 2. The effects of various
tablets inactive ingredients such as pregelatinized starch,
croscarmellose sodium, lactose monohydrate, magnesium
stearate and talc were also investigated. It was noticed that
none of them interfered in the determination at the levels
normally found in dosage forms.4. Analytical application
4.1. Analysis of spiked human plasma
In order to establish the analytical utility of the proposed
method, spiked human plasma samples were analyzed. Prior
to analysis samples were cleaned through solid-phase extrac-
tion technique. An excellent calibration curve was observed
over a wide concentration range 0.50–5.0 mg/mL (eight con-
centration levels) with a correlation coefﬁcient (r2) of 0.9984.
The calibration plot resulted in a straight line, ip/mA¼0.2350
C0
n(mg/mL)0.0395. Representative square wave voltammo-
grams are shown in Fig. 6 (A, curve b–i). No interference
peaks were observed in the blank plasma samples within the
studied potential range (Fig. 6A, curve a). Various statistical
parameters for linear regression equation were also calculated
and are listed in Table 1. Absolute recovery of Adefovir from
plasma was calculated from the related linear regression
equation, summarized in Table 2. Limit of detection
(0.17 mg/mL) and limit of quantiﬁcation (0.52 mg/mL) were
achieved by means of square wave voltammetric methods,
which proved the sensitivity of the method. The obtained
mean recoveries and standard deviation indicated good accu-
racy and precision of the proposed method (Table 2).
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Figure 6 Square-wave voltammograms of Adefovir extracted from
human plasma at different concentration levels, 0.5–5.0 mg/mL
(A, curves b–i) and plasma blank (A, curve a) and calibration curve
of Adefovir (B).
Table 3 Determination of Adefovir in different pharma-
ceutical formulations by proposed square wave voltammetric
methods.
Tablet Amount
labeled (mg)
Amount
founda (mg)
Error
(%)
Adesera 10.00 10.07 þ0.7
Adfovir 10.00 10.13 þ1.3
Adheb 10.00 9.89 1.1
aAmount found represents the average of six observations
(n¼6).
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The proposed square-wave cathodic adsorptive stripping voltam-
metric method was successfully applied for determination of
Adefovir in different pharmaceutical formulations without the
necessity for sample pretreatment or time-consuming extraction
steps prior to analysis. Adefovir contents were determined in
three different formulations, i.e. Adesera (Mfd. by Cipla Ltd.),
Adfovir (Mfd. by Sun Pharma Ltd.) and Adheb (Mfd. by
Ranbaxy-Rexcel). Firstly, tablets were weighed and crushed by
mortar pestle to a ﬁne powder. An accurately weighed amount of
powder was transferred to 10 mL volumetric ﬂask containing
5 mL of methanol, to ensure complete solubility of the drugcontents of the ﬂask were sonicated for 5 min and its volume was
made up to mark with methanol and centrifuged at 3500 rpm for
5 min. Clear supernatant liquid was withdrawn and diluted with
BR buffer of pH 3.8, so that ﬁnal concentration came under
working range. The square-wave voltammograms were recorded
under previously optimized conditions. The concentration of
Adefovir obtained by the proposed method in different pharma-
ceutical formulations was compared with labeled claimed and is
summarized in Table 3. Results show that Adefovir contents for
all pharmaceutical formulations fall within claimed amount with
error less than72.0%, indicating that method could be applied
for determination of Adefovir in pharmaceutical formulation.5. Conclusion
The developed method provides a sensitive and selective way
for determination of Adefovir in human plasma and pharma-
ceutical formulation. It was found that the developed method
is more sensitive for determination of Adefovir dipivoxil in
bulk and pharmaceutical formulation. This method is inex-
pensive, does not require large setup for pharmacokinetic
studies, any additional step for extraction of drug from matrix
like derivatization, further cleaning after extraction by dichlor-
omethane and evaporation after extraction. Thus, this devel-
oped method can be preferred over conventional methods for
quantiﬁcation of Adefovir in pharmaceutical formulation and
human plasma.Acknowledgments
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